Synthesis of Benzofuran Derivatives via Rearrangement and Their Inhibitory Activity on Acetylcholinesterase

Xiang Zhou 1, Miao Li 2, Xiao-Bing Wang 1, Tao Wang 2 and Ling-Yi Kong 1,*

1 Department of Natural Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, China
2 Jiangsu Center for Drug Screening, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, China

* Author to whom correspondence should be addressed: E-Mail: cpu_lykong@126.com; Tel.: +86-25-85391289; Fax: +86-25-85301528.

Received: 15 September 2010; in revised form: 18 November 2010 / Accepted: 24 November 2010 / Published: 29 November 2010

Abstract: During a synthesis of coumarins to obtain new candidates for treating Alzheimer’s Disease (AD), an unusual rearrangement of a benzopyran group to a benzofuran group occurred, offering a novel synthesis pathway of these benzofuran derivatives. The possible mechanism of the novel rearrangement was also discussed. All of the benzofuran derivatives have weak anti-AChE activities compared with the reference compound, donepezil.

Keywords: coumarin; benzofuran; rearrangement; anti-AChE

1. Introduction

Benzofuran derivatives are a major group of biologically active heterocycles, which are usually important constituents of plant extracts used in medicinal chemistry for their various biological activities [1-4]. Due to their diverse activities, much attention has been paid to synthetic strategies to access these systems, and a number of methods have been developed [5-7], but a method involving the rearrangement from a benzopyran group to a benzofuran group has not been reported before. More interesting to us, studies have shown that some of benzofuran derivatives such as donepezil [8] were able to inhibit acetylcholinesterase (AChE), or had the capability of reducing aggregated beta-amyloid
(Aβ) in the brain [9,10]. This prompted us to continued synthesizing benzofuran derivatives through the rearrangement of coumarins to expand our efforts on developing novel AChE inhibitors for treating Alzheimer’s disease (AD).

As we know, AChE and toxic Aβ are the main medication targets for treating AD so far, so dual binding AChE inhibitors [11], which can not only facilitate cholinergic transmission but also interfere with AD pathogenesis [12,13], namely the synthesis, deposition and aggregation of toxic Aβ in brain areas, have become the leading strategy for the development of anti-AD agents [14-17]. Hence developing novel dual binding AChE inhibitors is our particular interest and as part of our research program on naturally occurring biological coumarins [18-20], a series of novel coumarin derivatives has already been designed and synthesized aiming at AChE inhibitory activity [21]. As the extension of our efforts on developing new AChE inhibitors based on the coumarins, a novel series of derivatives were designed (Figure 1), but surprisingly, we did not obtain the target compounds during synthesis but rather an unusual rearrangement of the benzopyran group to a benzofuran group occurred instead, which offered a new synthetic pathway of benzofuran derivatives not reported before. Here, the details of the new rearrangement as well as the pharmacological characteristics of the new benzofuran derivatives obtained through this rearrangement are discussed.

Figure 1. Design strategy of the target compounds.

2. Results and Discussion

2.1. Chemistry

The synthesis of the benzofuran derivatives is shown in Scheme 1. The key intermediate 4-hydroxy-6-methylcoumarin (B) was prepared from p-cresol and malonic acid using ZnCl2 as the catalyst in POCl3 and the mixture was stirred at 60 °C for 24 h to give B. Then B was treated with POCl3 at reflux for 0.5 h to give 4-chloro-6-methylcoumarin (C). 4-morpholino-6-methylcoumarin (D) was obtained through the reaction between C and morpholine under reflux for 12 h. Compound D was brominated with NBS using BPO as the initiator to give 3-bromo-6-methyl-4-morpholinocoumarin (E) and not the expected 6-(bromomethyl)-4-morpholinocoumarin. Finally, E reacted with the corresponding piperazine substituents [22] and the rearranged compounds A1-A5 were obtained.
Scheme 1. The preparation of the target compounds.

Reagents and conditions: (a) p-cresol, ZnCl₂, malonic acid, POCl₃, 24 h, 60 °C; (b) POCl₃, triethylamine, 0.5 h, reflux; (c) K₂CO₃, morpholine, acetone 12 h, reflux; (d) NBS, BPO, CCl₄ under nitrogen, 8 h, reflux; (e) substituted phenylpiperazine derivatives, potassium carbonate, 15 mL acetone, 15 mL ethanol, 48 h, reflux.

The structures of the target compounds were elucidated by ¹H-NMR, IR and ESI-MS. In order to confirm their chemical structures, one of the target compounds, A₁, was further identified by single crystal X-ray diffraction (Figure 2).

Figure 2. The X-ray diffraction structure of compound A₁.
Through analyzing its chemical spectral data, the structure of D was identified as 6-methyl-4-morpholinocoumarin and that of E as 3-bromo-6-methyl-4-morpholinocoumarin and not the expected 6-(bromomethyl)-4-morpholinocoumarin, but A1 was identified as (4-phenylpiperazin-1-yl) (5-methyl-3-morpholino-benzofuran-2-yl) methanone, so it can be concluded that the rearrangement should have occurred in the step of synthesizing A from E. A possible mechanism of this transformation (shown in Scheme 2) is also discussed below. As to the position of bromination, after comparing the structure of D with the coumarin derivatives synthesized before [21], it can be noticed that the main difference between them was the substituents on the 4-position of the coumarin group, which was a basic morpholino group in D, while in the coumarin derivatives synthesized before it was a methyl, methoxy or chloro group, so the substituents on the 4-position of the coumarin group should be taken into account during the study of the position of bromination.

Scheme 2. A possible mechanism of the rearrangement.

2.2. Anti-AChE testing

To determine the therapeutic potency of the benzofuran derivatives A1-A5 for treating AD, their anti-AChE activities were assayed according to Ellmann’s method [23], utilizing freshly prepared AChE from rats brain homogenate and donepezil as the reference compound. Inhibition of AChE activities of them was shown in Table 1.

Table 1. Inhibition of AChE activities of the synthesized compounds.

| Compound | AChE inhibition (IC50, μmol/L) a | Compound | AChE inhibition (IC50, μmol/L) a |
|----------|---------------------------------|----------|---------------------------------|
| A1       | 45 ± 0.3                        | A4       | 11 ± 0.2                        |
| A2       | 32 ± 0.1                        | A5       | 21 ± 0.1                        |
| A3       | 73 ± 0.2                        | donepezil| 0.11 ± 0.01                     |

a Data are means ± standard deviation of three independent experiments.
In general, the data in Table 1 clearly shows that all of these compounds exhibited moderate inhibition activities toward the cholinesterase. Among them compound A4 (4-(p-tolylpiperazin-1-yl) (5-methyl-3-morpholinobenzofuran-2-yl) methanone showed the best AChE inhibitory activity with the IC_{50} value of 11 μmol/L.

3. Conclusions

By linking a substituted phenylpiperazine moiety to the benzofuran backbone conformationally restricted derivatives that are as potential inhibitors of AChE for treating AD were synthesized. An unusual rearrangement from a benzopyran group to a benzofuran group occurred. The rearrangement occurred under moderate conditions and offers a facile and practical preparation of biologically active benzofuran derivatives, so it may be worthwhile for developing potential AChE inhibitors through the rearrangement of benzopyran rings to benzofuran derivatives under mild conditions.

4. Experimental

4.1. General

Reaction progress was monitored using thin layer chromatography (TLC) on precoated Merck silica gel Kieselgel 60 F254 plates and the spots were detected under UV light (254 nm). Flash chromatography was performed with 230–400 mesh silica gel. The IR spectra were measured on a Jasco FT/IR-430 spectrophotometer. Melting points (mp) were obtained on a B-540 Buchi melting-point apparatus and are uncorrected. The 1H-NMR spectra were recorded on a 500 MHz Bruker spectrometer. The chemical shifts are reported downfield in ppm relative to internal TMS, and coupling constants are reported in Hertz (Hz). Mass spectra were run on a HP 5989A electrospray ionization mass spectrometer spectrometer. The mass spectra analysis is reported as m/z values.

4.2. 4-Chloro-6-methylcoumarin (C)

Compound B (0.005 mol) and triethylamine (0.005 mol) were added to POCl_{3} (5 mL). The mixture was refluxed for 30 min, and poured into water. Then the solution was extracted with methylene chloride. The methylene chloride layer was dried with anhydrous Na_{2}SO_{4} and evaporated under reduced pressure. Flash chromatography (cyclohexane-acetone = 10:1) was performed to give C 0.8 g (yield 82.3%); 1H-NMR (CDCl_{3}) δ: 7.56 (d, 1H, H-5, J = 2.1 Hz), 7.26 (dd, 1H, H-7, J = 2.1 Hz, 8.7 Hz), 7.28 (d, 1H, H-8, J = 8.7 Hz), 6.53 (s, 1H, H-3), 2.39 (s, 3H, 6-CH_{3}).

4.3. 6-Methyl-4-morpholinocoumarin (D)

Compound D was dissolved in acetone (50 mL), then the mixture was refluxed for 12 h., after which the reaction mixture was filtered and the filtrate was evaporated under reduced pressure. Flash chromatography (cyclohexane-acetone = 10:1) was performed to give D 0.97 g (yield 75.6%); 1H-NMR (CDCl_{3}) δ: 7.36 (d, 1H, H-5, J = 1.9 Hz), 7.31 (dd, 1H, H-7, J = 1.9 Hz, 8.5 Hz), 7.24 (d, 1H, H-8, J = 8.5 Hz), 5.73 (s, 1H, H-3), 3.24 [m, 4H, N(CH_{2})_{2}], 3.94 [m, 4H, (CH_{2})_{2}O], 2.41 (s, 3H, 6-CH_{3}).
4.4. 3-Bromo-6-methyl-4-morpholinocoumarin (E)

D (0.003 mol) were added to anhydrous CCl₄ (34 mL) with the reaction system protected by N₂. The mixture was refluxed for 0.5 h, then 1-bromopyrrolidine-2,5-dione (NBS, 0.0028 mol) and methyl benzoperoxoate (BPO, 100 mg) were added to the reaction mixture. After the reaction refluxed for 5 h, additional BPO (100 mg) was added again, and the reaction continued for 3 h. Then the reaction mixture was cooled down to room temperature and filtered. The filtrate was evaporated under reduced pressure. Flash chromatography (cyclohexane-acetone = 5:1) was performed to give E 0.32 g (yield 59.6%); ¹H-NMR (CDCl₃) δ: 7.36 (m, 1H, H-9), 7.34 (dd, 1H, H-7, J = 1.9 Hz, 8.4 Hz), 7.24 (d, 1H, H-6, J = 8.4 Hz), 3.54 [m, 4H, N₁(CH₂)₂], 3.93 [m, 4H, (CH₂)₂O], 2.44 (s, 3H, 10-CH₃). ¹³C-NMR (CDCl₃): 169.3 (C-3); 157.2 (C-1); 149.8 (C-8); 136.2 (C-5); 132.3 (C-6); 127.7 (C-4); 117.3 (C-7); 114.9 (C-9); 75.8 (C-2); 67.7(C-11 and C-12); 48.9 (C-10 and C-13); 22.3 (CH₃). ESI-MS: 325.3 ([M+H]+).

4.5. General synthetic procedure for target compounds A

E (1 mmol) was added to a mixture of acetone (15 mL) and ethanol (15 mL) containing a substituted piperazine derivative (1 mmol) and potassium carbonate (2 mmol). The mixture was refluxed for 48 h and the reaction mixture was evaporated. Flash chromatography was performed to afford the target compounds that were further purified by recrystallization from ethanol.

(5-Methyl-3-morpholinobenzofuran-2-yl)-(4-phenylpiperazin-1-yl) methanone (A₁) Yield 49%; colorless powder; mp 131–133 °C; IR (KBr) ν cm⁻¹: 3449, 2826, 1620, 1598, 1464, 1338, 1260, 1200, 1021, 902. ¹H-NMR (CDCl₃) δ: 7.58 (s, 1H, H-9), 7.44 (m, 1H, H-7), 7.22–7.28 (m, 3H, Ph, H-6), 6.82–7.00 (m, 3H, Ph), 3.61–3.84 (m, 8H, CH₂-15, CH₂-18, O(CH₂)₂), 3.15–3.20 (m, 8H, CH₂-11, CH₂-14, CH₂-16, CH₂-17), 2.42 (s, 3H, CH₃-10); ESI-MS: 406.2 ([M+H]+). CCDC number 740474 contains the supplementary crystallographic data for this compound. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif. Empirical formula, C₂₄H₂₇N₃O₃; molecular weight, 405.49; crystal dimensions, 0.40 × 0.34 × 0.25 mm; Orthorhombic, Pbca; a = 15.385 (2) Å, b = 7.301 (2) Å, c = 37.579 (3) Å; α = 90.00°, β = 90.00°, γ = 90.00°; V = 4221.3 (14) Å³; Z = 8; Dx = 1.276 Mg·m⁻³; R1 = 0.0546; ωR2 = 0.1205; GOOF = 1.055; θ = 1.71-25.01°; μ = 0.085 mm⁻¹; T = 298(2)K.

(4-o-Tolypiperazin-1-yl)-(5-methyl-3-morpholinobenzofuran-2-yl) methanone (A₂) Yield 43%; colorless powder; mp 122–125 °C; IR (KBr) ν cm⁻¹: 3424, 2954, 1617, 1518, 1385, 1259, 1158, 802; ¹H-NMR (CDCl₃) δ: 7.42 (s, 1H, H-9), 7.37 (m, 1H, H-7), 7.19~7.24 (m, 3H, Ph, H-6), 6.85~6.87 (m, 2H, Ph), 3.86~3.95 [m, 8H, CH₂-15, CH₂-18, O(CH₂)₂], 3.19~3.29 (m, 8H, CH₂-11, CH₂-14, CH₂-16, CH₂-17), 2.42 (s, 3H, CH₃-10); ESI-MS: 420.2 ([M+H]+).

(4-(4-Chlorophenyl)piperazin-1-yl)-(5-methyl-3-morpholinobenzofuran-2-yl) methanone (A₃) Yield 42%; colorless powder; mp 128–130 °C; IR (KBr) ν cm⁻¹: 2955, 2862, 1620, 1593, 1499, 1387, 1259, 1231, 813. ¹H-NMR (CDCl₃) δ: 7.43 (s, 1H, H-9), 7.29 (m, 1H, H-7), 7.19~7.24 (m, 3H, Ph, H-6),
6.85–6.87 (m, 2H, Ph), 3.73–3.88 [m, 8H, CH2-15, CH2-18, O(CH2)2], 3.21–3.29 (m, 8H, CH2-11, CH2-14, CH2-16, CH2-17), 2.42 (m, 3H, CH3). ESI-MS: 440.1 ([M+H]+).

(4-p-Tolylpiperazin-1-yl)-(5-methyl-3-morpholinobenzofuran-2-yl) methanone (A4) Yield 43%; colorless powder; mp 122–125 °C; IR (KBr) cm⁻¹: 2968, 2832, 1623, 1597, 1494, 1270, 1200, 1024, 917, 768; ¹H-NMR (CDCl3) δ: 7.42 (s, 1H, H-9), 7.30 (m, 1H, H-7), 7.16~7.21 (m, 3H, Ph, H-6), 7.01~7.04 (m, 2H, Ph), 3.70~3.90 [m, 8H, CH2-15, CH2-18, O(CH2)2], 2.96~3.31 (m, 8H, CH2-11, CH2-14, CH2-16, CH2-17), 2.45 (s, 3H, CH3-10), 2.34 (s, 3H, CH3). ESI-MS: 420.2 ([M+H]+).

(4-(4-Methoxyphenyl)piperazin-1-yl) (5-methyl-3-morpholinobenzofuran-2-yl) methanone (A5) Yield 39%; colorless powder; mp161–163 °C; IR (KBr) cm⁻¹: 2914, 2828, 1619, 1514, 1461, 1228, 1157, 816. ¹H-NMR (CDCl3) δ: 7.42 (s, 1H, H-9), 7.29 (m, 1H, H-7), 7.17 (m, 1H, H-6), 6.91 (m, 2H, Ph), 6.85–6.87 (m, 2H, Ph), 3.86~3.95 [m, 8H, CH2-15, CH2-18, O(CH2)2], 3.12–3.29 (m, 8H, CH2-11, CH2-14, CH2-16, CH2-17), 3.77 (s, 3H, OCH3), 2.42 (m, 3H, CH3-10). ESI-MS: 436.2 ([M+H]+).

4.6. In vitro AChE inhibition assay

AChE activity was measured in duplicate by the spectrophotometric method reported by Ellman et al. [23] with some modifications, mainly involving the source of the enzyme and the reference compound. Rat brain homogenate was used as the enzyme source. The whole brain except for the cerebellum was homogenized in nine volumes of 100 mM sodium phosphate buffer (pH 7.0). The test compounds were dissolved in dimethyl sulphoxide (DMSO). The AChE activity was expressed as a change in OD at 412 nm.

Acknowledgements

This research work was supported by the Chang Jiang Scholar Program of Ministry of Education, P. R. China (for L.-Y. Kong).

References and Notes

1. Rizzo, S.; Riviere, C.; Piazzì, L.; Bisi, A.; Gobbi, S.; Bartolini, M.; Andrisano, V.; Morroni, F.; Tarozzi, A.; Monti, J. F.; Rampa, A. Benzofuran-based hybrid compounds for the inhibition of cholinesterase activity, beta amyloid aggregation, and abeta neurotoxicity. J. Med. Chem. 2008, 51, 2883-2886.

2. Kirilmis, C.; Ahmedzade, M.; Servi, S.; Koca, M.; Kizirgil, A.; Kazaz, C. Synthesis and antimicrobial activity of some novel derivatives of benzofuran: Part 2. The synthesis and antimicrobial activity of some novel 1-(1-benzofuran-2-yl)-2-mesitylethanone derivatives. Eur. J. Med. Chem. 2008, 43, 300-308.

3. Filzen, G.F.; Bratton, L.; Cheng, X.M.; Erasga, N.; Geyer, A.; Lee, C.; Lu, G.; Pulaski, J.; Sorenson, R.J.; Unangst, P.C.; Trivedi, B.K.; Xu, X. Synthesis and SAR of selective benzothiophene, benzofuran, and indole-based peroxisome proliferator-activated receptor δ agonists. Bioorg. Med. Chem. Lett. 2007, 17, 3630-3635.
4. Dixit, M.; Tripathi, B.K.; Tamrakar, A.K.; Srivastava, A.K.; Kumar, B.; Goel, A. Synthesis of benzofuran scaffold-based potential PTP-1B inhibitors *Bioorg. Med. Chem.* **2007**, *15*, 727-734.

5. Nakamura, I.; Mizushima, Y.; Yamagishi, U.; Yamamoto, Y. Synthesis of 2,3-disubstituted benzofurans and indoles by \(\pi\)-Lewis acidic transition metal-catalyzed cyclization of ortho-alkynylphenol \(O,O\)- and \(N,O\)-acetals. *Tetrahedron* **2007**, *63*, 8670-8676.

6. Sakai, N.; Uchida, N.; Konakahara, T. Facile and efficient synthesis of polyfunctionalized benzofurans: Three-component coupling reactions from an alkynylsilane, an \(o\)-hydroxybenzaldehyde derivative, and a secondary amine by a Cu(I)–Cu(II) cooperative catalytic system. *Tetrahedron Lett.* **2008**, *49*, 3437-3440.

7. Zhang, J.W.; Zhang, Y.; Zhang, Y.S.; Herndon, J.W. Synthesis of benzofurans through coupling of dienylacetylenes with carbene complexes: Total synthesis of egonol. *Tetrahedron* **2003**, *59*, 5609-5616.

8. Sugimoto, H. Donepezil hydrochloride: A treatment drug for Alzheimer's disease. *Chem. Rec.* **2001**, *1*, 63-73.

9. Ono, M.; Kung, M.P.; Hou, C.; Kung, H.F. Benzofuran derivatives as Abeta-aggregate-specific imaging agents for Alzheimer's disease. *Nucl. Med. Biol.* **2002**, *29*, 633-642.

10. Allsop, D.; Gibson, G.; Martin, I.K.; Moore, S.; Turnbull, S.; Twyman, L.J. 3-p-Toluoyl-2-[4’-(3-diethylaminopropoxy)-phenyl]-benzofuran and 2-[4’-(3-diethylaminopropoxy)-phenyl]-benzofuran do not act as surfactants or micelles when inhibiting the aggregation of beta-amyloid peptide. *Bioorg. Med. Chem. Lett.* **2001**, *11*, 255-257.

11. Lorna, P.; Andrea, C.; Francesco, C.; Federica, B.; Manuela, B.; Francesca, M.; Maurizio, R.; Vincenza, A.; Angela, R. Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 423-426.

12. Wang, J.Z.; Wang, Z.F. Role of melatonin in Alzheimer-like neurodegeneration. *Acta Pharmacol. Sin.* **2006**, *1*, 41-49.

13. Walsh, D.M.; Selkoe, D. J. Deciphering the molecular basis of memory failure in Alzheimer's disease. *Neuron* **2004**, *1*, 181-193.

14. Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. *Science* **2002**, *297*, 353-356.

15. De Ferrari, G.V.; Canales, M.A.; Shin, I.; Weiner, L.M.; Silman, I.; Inestrosa, N.C. A structural mo-tif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation. *Biochemistry* **2001**, *40*, 10447-10457.

16. Inestrosa, N.C.; Alvarez, A.; Perez, C.A.; Moreno, R.D.; Vicente, M.; Linke, C.; Casanueva, O.I.; Soto, C.; Garrido, J. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: Possible role of the peripheral site of the enzyme. *Neuron* **1996**, *16*, 881-891.

17. Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. *Science* **2002**, *297*, 353-356.

18. Sugimoto, H.; Yamanishi, Y.; Imura, Y.; Kawakami, Y. Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors. *Curr. Med. Chem.* **2000**, *7*, 303-339.

19. Kryger, G.; Silman, I.; Sussman, J.L. Three-dimensional structure of a complex of E2020 with acetylcholinesterase from Torpedo californica. *J. Physiol. Paris* **1998**, *92*, 191-194.
20. Bartolucci, C.; Perola, E.; Pilger, C.; Fels, G.; Lamba, D. Three-dimensional structure of a complex of galanthamine (Nivalin) with acetylcholinesterase from Torpedo californica: Implications for the design of new anti-Alzheimer drugs. *Proteins* **2001**, *42*, 182-191.

21. Zhou, X.; Wang, X.B.; Wang, T.; Kong, L.Y. Design, synthesis, and acetylcholinesterase inhibitory activity of novel coumarin analogues. *Bioorg. Med. Chem.* **2008**, *16*, 8011-8021.

22. Zhang, C.E.; Yang, S.M.; Liu H. The study on the synthesis of 1-(2-methoxyphenyl)piperazine. *Appl. Chem. Ind.* **2002**, *31*, 32-34.

23. Ellman, G.L.; Courtney, K.D.; Andres, B.; Feartherstone, R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. *Biochem. Pharmacol.* **1961**, *7*, 88-95.

*Sample Availability:* Contact the authors.

© 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).